MED earnings analysis
What we found in MED's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Medifast's Q2 revenue was $76.4 million, down 27.6% year over year, and diluted EPS moved to a $0.28 loss from $0.22 of earnings. Revenue was approximately flat sequentially versus Q1, and gross margin improved sequentially to 69.9%, but year-over-year margin deleverage drove a $4.3 million operating loss. The balance sheet remains well funded with $169.8 million of cash, cash equivalents and investment securities, yet management expects the coach count—which fell from 22,800 to 11,700 year over year—to continue declining in 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Sequential sales and gross margin stabilized
- Sequential revenue was broadly stable at $76.4 million in Q2 versus approximately $76.0 million in Q1 2026, while gross margin improved 180 basis points sequentially to 69.9% from 68.1%.
- Coach productivity rose 41.0%
- Average revenue per active earning coach rose 41.0% to $6,529 from $4,630 a year earlier, despite the active coach base declining to 11,700.
- Liquidity remains substantial
- Cash, cash equivalents and investment securities increased $2.5 million to $169.8 million at June 30, 2026, and working capital increased $1.8 million to $160.5 million.
- Operating cash flow turned positive
- Six-month operating cash flow improved to $2.0 million from less than $0.1 million in the prior-year period, aided by a $14.9 million accounts-payable-and-accruals benefit.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Coach contraction continues to pressure revenue
- Q2 revenue fell $29.2 million, or 27.6%, year over year to $76.4 million as active earning coaches declined to 11,700 from 22,800. Management expects the number of active earning coaches to continue to decline during 2026.
- Volume deleverage widened operating loss
- Gross margin fell 270 basis points year over year to 69.9%, and operating margin deteriorated to negative 5.7% from negative 1.0%, reflecting lost fixed-cost leverage as volume declined.
- Profitability reversed to a net loss
- The company reported a $3.1 million net loss, or $0.28 per diluted share, versus $2.5 million of net income, or $0.22 per diluted share, a year earlier; Q2 operating loss increased to $4.3 million from $1.1 million.
- GLP-1 and macro pressures remain headwinds
- Management identifies GLP-1 adoption, inflation, commodity costs, food costs and potential tariffs as demand and cost risks. It notes approximately one-third of GLP-1 users discontinue after six months and up to 74% stop after one year, but GLP-1s remain a major competitive threat to the traditional client base.
- No formal risk-factor update; execution remains key
- The filing states there were no material changes to risk factors from the 2025 Form 10-K. However, six-month cash used in investing was $18.4 million, principally reflecting a $34.1 million net increase in investments, while new growth initiatives could affect liquidity in future periods.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.28
- Gross margin
- 69.9%
- Operating margin
- -5.7%
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management states that active earning coaches are expected to continue declining in 2026, while updated Trilivy products are expected to be fully brought to market in the current quarter.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 4, 2026
- Medifast reported a substantial decline in revenue and margins for Q1 2026, with revenue falling 34.3% year-over-year to $76.0 million. The company also experienced a larger net loss of $2.1 million, translating to an…
- 10-K · February 17, 2026
- Medifast reported a difficult 2025 with revenue down 36.0% to $385.8M and a net loss of $18.7M (GAAP diluted EPS of $(1.70)), driven primarily by a 40.6% decline in active earning coaches to 16,100. Management is…
- 10-Q · August 4, 2025
- Medifast reported Q2 revenue of $105,555,000 and GAAP diluted EPS of $0.22, marking a sharp improvement in profitability versus the prior-year quarter loss of $(0.75) per diluted share. Revenue remains materially below…
- 10-Q · April 28, 2025
- Medifast reported Q1 revenue of $115,728,000 (Q1 2024: $174,739,000), a year-over-year decline with gross margin largely stable at 72.8% but operating margin slipping to -1.1%. The company posted a net loss of $772,000…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MED makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever